→ A new microbiome startup, Israel’s BiomX, has raised $24 million in a Series A — OrbiMed, Johnson & Johnson Innovation and Takeda Ventures were in on the round, with participation from Seventure Partners, MiraeAsset, SBI Japan-Israel Innovation Fund and other European investors. BiomX is a preclinical biotech setting the stage for its first human study in the field of gut biology, which has attracted a number of new players over the past few years.
→ Just five days after announcing a collaboration deal with Pfizer to develop its gene therapy candidate SB-525 for hemophilia A, Sangamo announced that it has won fast track status for the program from the FDA.
→ After adding Valeant’s scalp to its belt, Citron Research has organized a new short attack on Exact Sciences $EXAS, saying that it cancer diagnostic test is inferior and will soon be outmoded as well. The report did not have a big impact on the stock though, which dipped 4% on Monday.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription